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Worldwide, the number of patients suffering from surgical complications account for a 
significant burden on healthcare systems.  Myocardial injury after non-cardiac surgery (MINS) 
is a new entity that has recently been identified as an independent risk factor associated with 
30-day all-cause mortality.  The risk of death increases approximately 10 fold following MINS
in the perioperative period.  Diagnosing myocardial injury in nonsurgical patients often relies 
on specific symptomatology and clinical findings combined with special investigations.  
However, in surgical patients, more than 80% of patients with postoperative myocardial injury 
will be asymptomatic, and hence the majority of diagnoses will be missed.  Studies identifying 
the prevalence and risk factors for MINS have been conducted in countries with a different 
surgical population to South Africa.  The primary outcome of this study was to investigate the 
prevalence of MINS after non-cardiac, elective, elevated risk surgery in South Africa.  
Methods 
Patients undergoing elevated risk, elective, non-cardiac surgery ≥ 45 years of age were enrolled 
via convenience sampling.  The new 5th generation, high sensitivity cardiac troponin T (hs-
cTnT) blood test was used to identify MINS.  Blood samples were taken between 24 to 72 
hours after surgery.  Exclusion criteria included patients with known renal disease, a recent 
cardiac event, pulmonary embolism or sepsis.   
Results 
A total of 244 patients were included in the study.  The prevalence of MINS was 4.9% (95% 
CI 2.2-7.6) which was not significantly different (p=0.078) to reports from international 
prospective observational studies. 
Conclusion 
Elective, elevated risk surgical patients in South Africa have a similar incidence of MINS when 
compared to patients from international studies.  As the risk profile of South African patients 
is significantly lower than other similar international observational studies, it is possible that 
the prevalence of MINS is more common in South Africa, when patients are adjusted for 
cardiovascular risk profile.  The burden of MINS on public health morbidity is therefore likely 
to be proportionally more in South Africa when compared to international reports.  This may 
suggest that the calibration of international cardiovascular risk prediction models is incorrect 
for South African patients, or there are confounding comorbidities which should be included 
in South African cardiovascular risk prediction models.  Larger studies are required to confirm 
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this hypothesis however, and should also aim to address the need for appropriate cardiovascular 
risk predicting models in South Africa, to ensure timeous identification of patients at risk of 
MINS. 
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Chapter 1 – Introduction and Literature Review 
Burden of surgical complications 
Weiser et al. (2008) estimated the global burden of surgery on healthcare systems to range 
between 187 and 281 million surgical cases per annum.[1]  Of these patients, 7 million will have 
major perioperative complications and approximately a million will experience mortality per 
year, indicating a significant impact on global healthcare, to which cardiovascular-related 
mortality contributes about a third.[2]  High-income countries appear to have a lower 
perioperative permanent disability- and death rate (0.4-0.8%), when compared to low and 
middle-income countries (5-10%), with general anaesthesia associated mortality as high as 1 
per 150 cases in certain parts of sub-Saharan Africa.[1]  According to the authors, nearly 50% 
of the perioperative complications were avoidable.  Therefore, the significance of perioperative 
morbidity and mortality is a well-established concern, as is the need to investigate potential 
risk factors and mitigating actions to prevent these.   
Elective and Non-elective surgical procedures 
Non-elective surgery carries a higher risk of complications when compared to elective 
procedures, demonstrated by studies done in all socio-economic environments.[3–5]  Many 
confounders, such as the inability to optimise medical co-morbidities and undiagnosed end-
organ damage add risk during non-elective surgery.  Planned, elective surgery would ideally 
allow for appropriate patient preparation and selection, in an effort to reduce the perioperative 
risk.  In a large, multicentre, international study, both elective and non-elective patients have 
been extensively investigated for myocardial injury after non-cardiac surgery (MINS).[5]  This 
study included patients from North- and South America, Europe, Australia and Asia.  However, 
investigators in the South African context have only published data on a single vascular 
surgical cohort.[6–8]  Since vascular surgery presents a specific high-risk profile, the data cannot 
simply be extrapolated to other surgical disciplines.  The prevalence of MINS in elective, high-
risk surgery, from all surgical disciplines, could provide new insight into perioperative 
medicine in the South African context.  It could either reassure clinicians about the safety 
associated with elective surgery in South Africa, or it could raise concern and serve as a 
sobering push towards furthering research and developing preventative strategies to avoid 
MINS in the perioperative period. 
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Defining surgical risk 
Various international task forces have published guidelines and recommendations regarding 
the perioperative evaluation and care of patients for non-cardiac surgery. In 2007, the American 
College of Cardiology and American Heart Association (ACC/AHA), described their three risk 
categories based on the likelihood of developing significant perioperative major adverse 
cardiac events (MACE): low (less than 1%), intermediate (1 – 5%) and high (above 5%).[9]  In 
2014, a more pragmatic distinction between low (less than 1%) and elevated risk (greater than 
1%) was used to describe the cumulative patient- and surgery-specific risk.[10]   
Impact of MINS 
In a large, multicentre study, Devereaux et al evaluated the association between myocardial 
injury after non-cardiac surgery and mortality (Vascular Events In Non-cardiac Surgery 
Patients Cohort Evaluation Study – VISION 2012).[5] Patients that suffered a troponin elevation 
had a significantly elevated risk of 30-day mortality.   Myocardial injury was subsequently 
defined as an elevated cardiac troponin T (cTnT) which was attributed to myocardial ischaemia 
following noncardiac surgery.[12]  Subsequent analysis of the data compared risk factors and 
identified a troponin elevation as the strongest predictor of mortality, with an odds ratio (OR) 
of 10.07 (95% confidence interval 7.84 – 12.94).[12]  MINS occurred in 8% of patients.[12]  One 
in ten patients that experienced MINS died within 30 days of surgery.  The vascular surgical 
cohort that has been studied in South Africa, found an incidence of MINS of 13.5%.[13]  The 
causes of death from the VISION study were found to be approximately equally divided 
between vascular- and non-vascular deaths.  In other words, having an elevated cTnT during 
the acute post-operative period increased all-cause mortality.  While the predictive power of 
post-operative troponin elevations are clear, an editorial in Circulation (2013) emphasised that 
practitioners should be aware of its lack of specificity in identifying the exact cause of death.[14]  
Troponin elevation was not able to demonstrate increased risk of cardiac death, but rather 
functioned as a marker of overall hazard.  However, the VISION study investigators attempted 
a rational explanation for this phenomena.  They concluded in their discussion that MINS is 
likely to contribute to mortality even if the eventual cause of death is non-vascular, such as 
pneumonia, and that a patient that develops MINS will likely be at a physiological disadvantage 
at dealing with additional perioperative complications, which might have been insignificant, 
should they have occurred in the absence of MINS.  MINS is independently associated with 
both vascular- and non-vascular deaths.[12] 
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The impact of MINS has also influenced international perioperative management guidelines.  
In the 2007 ACC/AHA guidelines for non-cardiac surgery evaluation, post-operative troponin 
surveillance is only recommended in symptomatic patients with electrocardiogram (ECG) 
changes.[9,10]  The European Society of Cardiology and the European Society of 
Anaesthesiology (ESC/ESA) guidelines of 2014, promotes the pre- and postoperative use of 
troponin screening, but only in high risk patients.[15]  While the Third Universal Definition of 
Myocardial Infarction taskforce also imply that troponin surveillance in high risk patients 
might be considered, the ESC/ESA guidelines provide a definition for what they regard as high 
risk patients: poor functional capacity with metabolic equivalents (METs) of less than or equal 
to 4, or a revised cardiac risk index (RCRI) of greater than 1 for vascular surgery or greater 
than 2 for non-vascular surgery.[15,16]  The European guidelines further note that troponin 
screening provides additional prognostic value.  A review in 2016 stated that the majority of 
clinicians do not appreciate the significance of MINS, and suggested an approach to 
incorporate perioperative cTnT surveillance in daily practice.[17]  However, in 2017, the 
Canadian Cardiovascular Society (CCS) provided perioperative guidelines that incorporated 
strong recommendations for postoperative troponin surveillance.[18]  Troponin surveillance is 
recommended in patients above 45 years with additional risk factors (elevated RCRI or other 
cardiac biomarkers) and routinely in patients above 65 years of age.  While the rest of the 
international guidelines are still ambivalent, the recent addition of cTnT surveillance to the 
2017 CCS guidelines suggest that the international perioperative community is moving towards 
troponin surveillance becoming daily practice.  Despite the availability of the cTnT test 
increasing in South Africa, it will likely be some time before this becomes common practice, 
especially in resource limited facilities.  It is therefore important to investigate troponin 
screening in the South African context. 
MINS – Pathophysiology, Clinical presentation and Diagnosis 
Approximately 30% of mortality after non-cardiac surgery are as a result of cardiovascular 
complications.[2]  A brief review of the pathophysiology of MINS aims to clarify its impact on 
the perioperative period. 
Myocardial injury (MI) is a term extensively used in medical literature, ranging from the 
emergency room to the operating theatre.  The cause and clinical presentation can differ 
significantly.  The primary event leading to MI might originate from a variety of pathological 
processes.  Interrupted blood supply, imbalanced oxygen supply and demand, poorly 
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oxygenated blood and blood with inadequate oxygen carrying capacity can all result in MI.[16]  
They can occur as solitary events or in combination.  A review article focusing on the 
pathophysiology of perioperative myocardial infarction noted the dissimilarity between 
medical patients with myocardial infarction and myocardial infarction during the perioperative 
period.[19]  The vast majority of patients with acute myocardial infarctions that present to the 
emergency room, will suffer from an acute occlusive vascular cause, such as plaque rupture or 
thrombosis.  This differs to most of the patients that suffer a perioperative myocardial injury.  
Post-mortem studies identified oxygen supply-demand imbalance as the major contributor to 
myocardial injury within the first 3 to 4 days after surgery, while plaque rupture occurred at 
random intervals within the first 17 days.  This finding supports the hypothesis that MINS is 
likely as a result of a relative hypoperfusion of the coronary arteries, possibly aggravated by 
an increased myocardial oxygen demand in the first few days after surgery.  This aggravation 
might be due to the increased basal metabolic rate associated with surgery, pain, post-operative 
respiratory complications, coagulation disturbances or anaemia.  Recent publications have 
investigated perioperative haemodynamic effects on myocardial injury.  Intraoperative 
hypotension, defined as a mean arterial pressure (MAP) of less than 55 mmHg, significantly 
increased the occurrence of myocardial injury.  The magnitude of impact was also time-
dependent, with a duration above 20 minutes resulting in a significant increase in 30-day 
mortality.[20]  Another publication found a statistically significant association between 
preoperative baseline heartrate and myocardial injury.[21]  The study concluded that elevated 
heart rate, especially above 96 beats per minute, increased the risk of myocardial injury and 
mortality within 30 days.  Although plaque rupture appears to contribute to perioperative 
myocardial injury, it does not appear to occur more commonly in the early postoperative 
time.[19]  Another finding was that patients with established coronary artery disease, had an 
increased risk of perioperative MI.  The pathophysiological process behind perioperative MI is 
therefore different when compared to medical MI. 
While the basic pathological process that result in MI is likely caused by lack of adequate 
oxygen supply to the myocardium, the way in which this presents can vary.  MI seen in the 
emergency room is commonly associated with the clinical symptoms and signs defined by the 
Third Universal Definition of Myocardial Infarction.[16]  This definition includes symptoms of 
ischaemia, ECG changes, altered cardiac imaging studies and deranged cardiac biomarkers.  Of 
note, is the requirement of clinical symptoms and signs in addition to elevated biomarkers.  
MINS presents as a different clinical entity.  Of great concern is the fact that the majority of 
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patients (more than 84%) that experience MINS, do not have ischaemic symptoms and 
therefore do not fulfil the diagnostic criteria.[12]  ECG abnormalities occurred in less than 35% 
of patients with MINS, significantly reducing the predictive utility thereof.[12]  If perioperative 
physicians were to rely on current guidelines to diagnose MI in the perioperative period, they 
will miss the majority of patients that experience MINS.[22]  MINS was introduced as a new 
diagnostic entity because of its independent manner in which it influences perioperative 
outcome and its unique presentation.[12,22]  Elevated cardiac biomarkers, specifically cTnT, 
therefore forms the cornerstone of diagnosing MINS in the perioperative phase.  
Cardiac Troponin T 
The physiological basis of muscle contraction applies to both skeletal- and cardiac muscle.  
Appropriate interactions between muscular structural proteins are required for contraction to 
occur.  Troponin is one such protein.  When injury occurs to myocardial muscle, these structural 
proteins are released into the circulation.[23]  This troponin leak can then be quantified.  Earlier 
generations of troponin tests had significant cross-reaction with skeletal muscle.  Newer assays 
are now able to detect cardiac-specific troponin.  The cardiac troponins T and I have been 
utilised as markers of myocardial damage.  Both troponins have been implicated successfully 
in the diagnosis of MINS.[22]  Universal standardisation of the Troponin I test have been a 
concern, hence Troponin T tests have been used more commonly.[24]  With recent advances in 
technology, the sensitivity of troponin T detection has also increased.[25]  Troponin tests prior 
to the latest 5th generation were unable to detect down to single digits in the ng/L range.  This 
resulted in the inability to accurately quantify the true population normal.  According to 
recommendations found in the universal definition of myocardial infarction, diagnostic cardiac 
biomarkers should be sufficiently sensitive to allow the calculation of the upper limit of normal 
(99th percentile) with a coefficient of variation (CV) of 10% or less.[16,24,26]  The fourth 
generation cTnT test had a lower limit indicated by a result of <0.01 μg/L (<10 ng/L).[25]  In 
other words, once the troponin level reached 10 ng/L or lower, the test was no longer 
representative.  The upper reference of normal for the 4th generation cardiac troponin T was 
found to be 0.03 μg/L (30 ng/L).[27]  Current 5th generation cTnT has a lower limit of 3-5 
ng/L.[27]  An upper limit of normal of 13 ng/L (10% CV), was calculated.[25,27]  This had a 
significant impact on how the diagnosis of acute myocardial ischaemia was made.  Troponin T 
levels above 13 ng/L are now regarded as elevated, a remarkable change from the World Health 
Organisation (WHO) definition of greater than 0.1 μg/L (>100 ng/L) from the 1970’s.[27]  Of 
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course, specific troponin cut offs will apply to specific clinical scenarios.  A review article 
discussing the statistical implications of diagnostic tests highlights the importance of pre- and 
post-test probability, and how the need for a specific sensitivity or specificity can alter 
diagnostic test requirements.[28]  Certain clinical scenarios would benefit from a more sensitive 
test as opposed to a test with greater specificity but reduced sensitivity.  A good example would 
be an acute myocardial infarction in the emergency room.  In a patient with risk factors for and 
clinical signs of myocardial ischaemia, the pre-test probability for a positive troponin leak 
would be high.  A false negative might therefore have more harmful implications for patient 
care and prognosis as opposed to a false positive.  Comparing the 4th generation cTnT with the 
latest 5th generation test, illustrates how it has evolved.  The sensitivity of the diagnosis of acute 
myocardial infarction within nine hours of the event has increased from just over 80% to nearly 
100%.[27]  Specificity has reduced from approximately 99% to just over 75%.  With a sensitivity 
of nearly 100%, the occurrence of false negatives is almost excluded.  The hs-cTnT can 
therefore rule out the diagnosis of acute myocardial infarction with great accuracy at the cost 
of some specificity.  The need to establish proper normal ranges, and a 99th percentile for 
specific population groups are therefore important.  Statistical analysis revealed that a 4th 
generation cTnT of greater than 0.03 μg/L (>30 ng/L) were significant in predicting 30-day 
mortality (aHR 4.30; 95% CI, 2.68–6.91).[12]   
To be able to utilise 5th generation cut offs for MINS a correlation with the 4th generation cTnT 
test is required.  Some literature suggesting correlating values exist.  Studies comparing 4th- 
and 5th generation cTnT tests suggest a 4th generation test value of 30 ng/L comparing to 
approximately 53 ng/L of the 5th generation test, while 20 ng/L (4th generation) compares to 40 
ng/L (5th generation).[29,30]  Another study investigated the proportion of patients that have 
elevated hs-cTnT after non-cardiac, elective surgery.[31]  A 95th percentile was calculated for 
postoperative hs-cTnT of 33 ng/L, of which the prevalence matched the cumulative proportion 
with 4th generation cTnT above 30 ng/L.  In the light of these developments, the prevalence of 
both 33 ng/L and 53 ng/L troponin leaks, using the 5th generation test, have been included in 
this study. 
Troponin elevation from other causes 
The pathophysiology of troponin leaks after myocardial ischaemia may be either from 
increased myocardial oxygen demand or decreased supply, and results in myocardial cellular 
dysfunction.  This dysfunction can lead to cell damage or cellular death, and is followed by 
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troponin proteins leaking into the circulation.  Non-ischaemic causes of troponin leaks are less 
well understood, while the predictive impact on perioperative mortality is unaffected.[32]  
Various associations with troponin elevation have been described, such as carbon monoxide 
poisoning, renal failure, heart failure, acute pericarditis, acute exacerbation of chronic 
obstructive airway disease, chemotherapy-related myocardial damage, pulmonary arterial 
hypertension, pulmonary embolism, sepsis (previously defined as severe sepsis or septic 
shock), stroke and sub arachnoid haemorrhage.[33–44]  Within the context of a different cause of 
troponin elevation, its specificity for disease is lost, but its predictive power on mortality 
appears to remain intact.  In a recent article, mortality and functional status were predicted with 
equal or improved accuracy, when compared to existing tests for evaluating the severity of 
pulmonary arterial hypertension.[41]  However, in non-surgical patients with renal impairment, 
studies have shown that cTnT elevations occur without evidence of myocardial ischaemia.[34–
36] Some studies also evaluated the prognostic value of elevated cTnT in renal patients and
failed to demonstrate a significance during long-term follow-up.  Whether this can be applied 
in the perioperative milieu is debatable since data from the VISION trial demonstrated that, 
regardless of estimated glomerular filtration rate, the prognostic value of cTnT elevation 
remained consistent in the perioperative setting.[5]  The significance might be better 
demonstrated if one can distinguish between an acute postoperative cTnT elevation and a 
relative increase from an existing elevated cTnT at baseline.  An acute elevation from 
undetectable levels to 500 ng/L (in other words, a change in cTnT of +500 ng/L) might herald 
a worse prognosis as opposed to an elevation from 480 ng/L to 500 ng/L (a change in cTnT of 
+20 ng/L).  A recent study evaluated troponin changes during the perioperative period and
found a significant proportion of high risk patients to have an elevated hs-cTnT even before 
surgery, which predicted the long- and short term postoperative morbidity and mortality in 
these patients.[45]  The study also demonstrated an increased mortality risk when an absolute 
rise in pre-existing elevated cTnT occurred.  In summary, a conclusion can be made that other 
disease entities may lead to an elevated cTnT.  Although a large proportion of those disease 
states have shown that those elevated biomarkers have prognostically relevant data, it cannot 
be applied universally in non-surgical patients.  In the perioperative period, troponin elevations 
appear to be a more robust prognostic marker, whether it be pre- or post-operatively.  Ideally, 
cardiac troponin surveillance should commence before elevated risk surgery. 
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South African surgical population and MINS 
The European Surgical Outcomes Study (EuSOS) evaluated in-hospital mortality over a 7-
day period.  The study included over 40 000 patients from 28 European nations and excluded 
patients undergoing cardiac surgery.[3]  The recent South African Surgical Outcomes Study 
(SASOS) closely matched the EuSOS in terms of patient selection and methodology.[4]  The 
VISION trial included all surgeries performed on patients above 45 years of age and also 
reported on various risk factors and mortality.[5]  A comparison between EuSOS and SASOS 
indicated that the South African surgical patients were significantly younger, had an overall 
lower American Society of Anesthesiology grading and a lower proportion of elevated risk 
surgery (all comparisons had a p value less than 0.01).[4]  This could explain the elevated 
mortality witnessed in the EuSOS study (4.0% compared to 3.1%; p value is 0.006).[4]  More 
South African patients underwent non-elective surgery when compared to both EuSOS and 
VISION data.  To compare South African patients to the VISION data, we compared all 
patients >=45 years of age from the SASOS cohort with VISION.  Statistical comparisons 
were done using Χ2 with Yate’s correction.  South African patients were once again younger 
but more exposed to elevated risk surgery (see Table A).  These comparisons illustrate the 
significant differences between elective surgical patients in South Africa and the rest of the 
world, which forms an important rationale for this study. 
Table A. Comparison between the >= 45 year old cohorts of the South African Surgical 
Outcomes Study (SASOS) and the Vascular events In noncardiac Surgery patIents 
cOhort evaluatioN (VISION) Study [5,4] 

























Elective surgery n (%) 989 (58.2) 12991 (85.8) <0.001 
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Current proposed management of MINS 
Large, randomised controlled trials that evaluate specific treatment modalities for MINS, are 
currently lacking.  Most recommendations are based on observational data.  Currently, simple 
therapeutic measures are advocated to improve patient outcomes.  A reanalysis of the data 
from the PeriOperative ISchemic Evaluation (POISE) trial of 2008 suggests that once MINS 
occurs, addition of aspirin and statin therapy could positively impact postoperative 
survival.[11]  Another study investigated patient outcomes in a vascular cohort of 667 patients, 
all of which suffered MINS.[46]  A comparison was made between those patients that received 
medical treatment intensification (defined as introducing or increasing any of these four 
cardiovascular drug groups; antiplatelet agents, β-blockers, statins, or angiotensin converting 
enzyme inhibitors) during the postoperative period, and those that did not.  The cohort that 
did not receive intensified therapy had a hazard ratio (HR) of 1.77 (95% CI 1.13–2.42; 
p=0.004) of one-year mortality compared to those that were provided with treatment 
intensification.[46]  Practice guidelines promote the involvement of other medical specialities 
to include a multidisciplinary team once MINS occurs.[17,18,22]  Recommendations also 
suggest further investigational workup, increasing surveillance and providing haemodynamic 
optimisation for patients that are diagnosed with MINS.  Trials on specific therapies for 
MINS are ongoing.[17]  In summary, current treatment modalities involve simple therapeutic 
measures, such as the introduction of aspirin and a statin, increasing the monitoring of the 
patient (high care environment with continuous monitoring) and optimisation of myocardial 
oxygen delivery (treat hypotension, anaemia and pain). 
Summary 
The burden of complications after surgery has a significant impact on global healthcare.  
Studies indicate that cardiovascular complications play a significant role and suggest that a 
large proportion of those complications can be avoided.  Myocardial injury after non-cardiac 
surgery (MINS) has been identified as a unique clinical entity with a significant impact on 
mortality.  Its predominantly asymptomatic presentation renders clinical symptoms and signs 
less useful at establishing a diagnosis.  Cardiac troponin elevation has been implicated as an 
accurate marker of MINS, although unable distinguish between vascular or non-vascular 
causes of death, its prognostic value in the perioperative field remains robust.  Newer 
generations of the test have increased sensitivity and still provide significant predictive data 
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in the perioperative period.  Most of the current data represent patient populations that differ 
from South Africa.  South African patients appear to have different risk profiles.  
Investigating the prevalence of MINS in the non-cardiac, elective, elevated risk surgical 
population has not yet been conducted, and could provide a unique insight into South African 
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Worldwide, the number of patients suffering from surgical complications account for a 
significant burden on healthcare systems.  Myocardial injury after non-cardiac surgery (MINS) 
is a new entity that has recently been identified as an independent risk factor associated with 
30-day all-cause mortality.  The risk of death increases approximately 10 fold following MINS
in the perioperative period.  Diagnosing myocardial injury in nonsurgical patients often relies 
on specific symptomatology and clinical findings combined with special investigations.  
However, in surgical patients, more than 80% of patients with postoperative myocardial injury 
will be asymptomatic, and hence the majority of diagnoses will be missed.  Studies identifying 
the prevalence and risk factors for MINS have been conducted in countries with a different 
surgical population to South Africa.  The primary outcome of this study was to investigate the 
prevalence of MINS after non-cardiac, elective, elevated risk surgery in South Africa.  
Methods 
Patients undergoing elevated risk, elective, non-cardiac surgery ≥ 45 years of age were enrolled 
via convenience sampling.  The new 5th generation, high sensitivity cardiac troponin T (hs-
cTnT) blood test was used to identify MINS.  Blood samples were taken between 24 to 72 
hours after surgery.  Exclusion criteria included patients with known renal disease, a recent 
cardiac event, pulmonary embolism or sepsis.   
Results 
A total of 244 patients were included in the study.  The prevalence of MINS was 4.9% (95% 
CI 2.2-7.6) which was not significantly different (p=0.078) to reports from international 
prospective observational studies. 
Conclusion 
Elective, elevated risk surgical patients in South Africa have a similar incidence of MINS when 
compared to patients from international studies.  As the risk profile of South African patients 
is significantly lower than other similar international observational studies, it is possible that 
the prevalence of MINS is more common in South Africa, when patients are adjusted for 
cardiovascular risk profile.  The burden of MINS on public health morbidity is therefore likely 
to be proportionally more in South Africa when compared to international reports.  This may 
suggest that the calibration of international cardiovascular risk prediction models is incorrect 
for South African patients, or there are confounding comorbidities which should be included 
in South African cardiovascular risk prediction models.  Larger studies are required to confirm 
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this hypothesis however, and should also aim to address the need for appropriate cardiovascular 




Recent reports estimate the global, annual perioperative morbidity and mortality rates at 
approximately 3% and 0.5% respectively.[1]  To appreciate the impact on healthcare systems, 
those proportions translate into major perioperative complications in approximately 7 million 
patients, of which mortality occurs in 1 million in the immediate perioperative period per 
annum, since over 200 million surgeries are performed worldwide per year.[1]  Studies from 
high-income countries suggest that 50% of major adverse perioperative events could be 
avoided.[1]  Research on the cause- and prevention of perioperative complications can therefore 
benefit global healthcare. 
Perioperative risk has recently been redefined according to the American College of 
Cardiology and American Heart Association (ACC/AHA) task force on perioperative cardiac 
evaluation and management publication.[2]  Cumulative patient- and procedure specific risk for 
developing a major cardiac adverse event (MACE), such as death or cardiac arrest, can be 
divided into low- (less than 1% risk) or elevated risk (equal to or below 1% risk).   
Cardiovascular deaths contribute a third to non-cardiac perioperative mortality.[3]  A large, 
multicentre, international study investigated more than 15 000 patients from North- and South 
America, Australia, Europe and Asia (Vascular Events In Non-cardiac Surgery Patients Cohort 
Evaluation Study – VISION 2012).[4]  30-day mortality was found to be independently 
associated with an elevated cardiac biomarker, specifically cardiac troponin T (cTnT).  It was 
not only the strongest predictor of mortality, but the magnitude of troponin elevation also 
correlated with risk.  Subsequently, myocardial injury after non-cardiac surgery (MINS) was 
defined as an elevated cTnT, predicting mortality with an odds ratio (OR) of 10.07 (95% CI 
7.84 – 12.94).[5]   
Medical- and perioperative patients differ in terms of the clinical presentation of myocardial 
ischaemia.[6]  Non-surgical guidelines rely on clinical symptoms and signs in addition to 
positive special investigations (electrocardiogram, cardiac biomarkers, cardiac imaging 
studies) to diagnose myocardial infarction.[7]  Unfortunately, approximately 84% of 
perioperative patients with myocardial injury will be asymptomatic, resulting in clinicians 
missing the diagnosis in the vast majority of patients with MINS.[5]  A recent review suggests 
that its silent presentation and the lack of high grade evidence for therapeutic interventions, 
could explain perioperative clinicians’ hesitance towards adopting MINS as a significant 
perioperative event.[8]  However, it is clear that MINS is associated with a significant public 
health burden associated with mortality and significant morbidity.[5]  
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Cardiac biomarkers utilised for the diagnosis of myocardial infarction require pre-defined 
reference limits.  These limits or cut-off values are derived from healthy individuals.[9–11]  With 
technological advances, the sensitivity of more recent generations of cTnT has increased.[11,12]  
For the first time, the 99th percentile, or upper reference of normal, can be determined in 
reference populations by using the latest 5th generation high sensitivity cardiac troponin T (hs-
cTnT) test.[12]  Only the latest hs-cTnT test satisfies the current guidelines’ suggestion that the 
upper reference limit should be calculated as the 99th percentile from a reference population 
with a coefficient of variation (CV) of 10% or less.[7,12]  This 99th percentile has been calculated 
by various studies and found to be approximately 14 ng/L.[11,12]  While this has increased the 
sensitivity of the test remarkably, it has done so at the cost of specificity.[11]  In terms of the 
diagnosis of acute myocardial infarction in medical patients, the sensitivity has increased to 
nearly 100%, almost eliminating false negatives.  In terms of perioperative troponin 
surveillance, the increased sensitivity added complexity to the interpretation thereof.  The 
VISION study utilised the previous 4th generation cTnT test.[4]  Various statistical models were 
tested, but MINS was finally defined as an isolated 4th generation cTnT of 30 ng/L (0.03 
μg/mL) or more that was due to myocardial ischaemia.[5]  Troponin elevation predicted 30-day 
mortality independently.  Correlations between the 4th- and 5th generation cTnT test do exist.  
While a 4th generation cTnT level of 30 ng/L correlates with a 5th generation cTnT (hs-cTnT) 
level of approximately 53 ng/L, another study suggests that the 95th percentile of perioperative 
patients were 33 ng/L (95% CI: 26–49) for hs-cTnT.[13,14]  The latter study was a sub-study 
from the VISION Bio-Bank.  The cumulative proportion of patients with a 4th generation cTnT 
above 30 ng/L were 9%, while those with a hs-cTnT > 33 ng/L matched that of the 4th 
generation cTnT (7 – 10%).   
Troponin elevation can also be caused by non-ischaemic causes.  Carbon monoxide poisoning, 
renal failure, heart failure, acute pericarditis, acute exacerbation of chronic obstructive airway 
disease, chemotherapy-related myocardial damage, pulmonary arterial hypertension, 
pulmonary embolism, sepsis, stroke and subarachnoid haemorrhage can all result in cTnT 
elevations.[15–26]  Not all of these elevations appear to impact prognosis consistently, especially 
in non-surgical patients.  In the perioperative milieu, however, cTnT elevation appears to be 
much more robust at predicting outcome, and is independently associated with both vascular 
and non-vascular causes of mortality.[5,27]  Pre-operative hs-cTnT elevation, as well as an 
absolute rise of greater than 9 ng/L hs-cTnT had significant short- and long term effect on 
perioperative mortality.[28] 
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In terms of MINS, investigators in South Africa have only published data on a single vascular 
surgical cohort.[29–31]  These reports also concluded that locally derived prognostic markers 
would probably be more appropriate in risk stratifying the South African surgical population.  
Since the prevalence of MINS in the non-cardiac, elective, elevated risk surgical population 
has not yet been established, it could provide a unique insight into South African surgical 
patients and their potential postoperative outcomes. 
Hypothesis 
The prevalence of MINS in elective, non-cardiac, elevated risk surgical patients is not well 
established in South Africa.  Because of the different patient characteristics and risk profiles, 
extrapolation of the prevalence of MINS in South African surgical patients from international 
data is undesirable, and is the principle indication for this study.  The null hypothesis for this 
study was that the prevalence of MINS would be similar in our South African study population 
to other peer-reviewed international publications. 
The primary objective of this study was to determine the prevalence of myocardial injury after 
non-cardiac surgery in the elective, elevated risk surgical population. 
Methods 
Study Design 
This was a prospective, single centre, observational study investigating the prevalence of 
myocardial injury after non-cardiac surgery at Groote Schuur Hospital.  After approval from 
the Human Research Ethics Committee of the University of Cape Town, data collection 
followed informed patient consent, and convenience sampling from 2014 to 2016.  To conform 
to international standards, a Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) checklist was followed and completed.[32] 
Statistical analysis was done using Minitab 17 Statistical Software.[33]  Continuous variables 
were described using sample mean and standard deviation (SD) and categorical variables using 
sample median and interquartile range (IQR).  Where statistical comparisons were made 
between continuous variables, the unpaired t-test was used, while categorical data were 
compared using the X2 test, or the X2 test with Yates’s correction, as appropriate. 
Patient Population 
41 
Patients ≥ 45 years of age, presenting for elective, elevated risk, non-cardiac surgery were 
eligible.  Elevated risk surgery was defined as all surgery with a predicted risk of MACE of 
greater than 1%.[2]  These include all intra-abdominal-, non-cardiac thoracic-, joint 
replacement-, major orthopaedic- and vascular surgery.   
Investigation 
Enrolled patients were investigated for myocardial injury after non-cardiac surgery (MINS), 
defined by an elevated post-operative high sensitivity cardiac troponin T suspected to be due 
to myocardial ischaemia, and no other known non-ischaemic causes of troponin elevation.  
Sampling protocol and procedure 
Theatre lists were interrogated and patients were identified with appropriate inclusion criteria.  
Patients were selected by means of convenience sampling.  Post-operative informed consent 
was taken and blood samples were collected within 24 to 72 hours of surgery.  The majority of 
patients (91%) were sampled once within 24 hours.  In some patients a second sample was 
taken within 72 hours.  In patients with two samples, the highest troponin elevation was 
recorded.  Specimens were analysed using Troponin T hs (high sensitive) immunoassay from 
Roche Diagnostics (Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim, 
Germany). 
Exclusion Criteria 
Exclusion criteria included emergency surgery, recent myocardial infarction or pulmonary 
embolism, renal dysfunction and sepsis as judged by the attending anaesthetist and pre-existing 
hypotension.  Low risk surgery, such as ophthalmic- and superficial plastic surgery were also 
excluded.  As sampling only commenced after surgery, we could not exclude pre-existing cTnT 
elevation.  Therefore, myocardial infarction, pulmonary embolism, sepsis and renal 
dysfunction were exclusions because of their direct or indirect influence on measured 
postoperative cTnT.  Renal impairment was defined using international guidelines.[34,35] 
Outcomes 
The primary outcome was the prevalence of MINS, defined as an elevated high sensitivity 
cTnT of above 33 ng/L.     
Secondary outcomes were to investigate risk factors such as patient demographics, surgical 
categories and co-morbidities associated with MINS.  
Sample Size 
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Based on previous studies, a prevalence of MINS of 10% to 15% was estimated for the study 
population in question.  Statistical calculation revealed a required sample size of 219 to 266 for 
a narrow confidence interval width of 10%.  A sample size of 300 was targeted.  
Results 
Approximately 1100 patients were screened of which 301 were eligible.  After exclusions, 244 
patients were included in the study.  The flow diagram of patient recruitment is shown in figure 
1.  
Insert figure 1 
The patient characteristics, surgical categories and comorbidities are shown in tables 1 to 3. 
The majority of patients were in the younger age category, from the ages of 45 to 65 years.  
General- and gynaecological surgery were the most common surgeries performed, which might 
explain the increased proportion of female participants.  Hypertension and malignancy were 
the most frequently recorded comorbidities.     
Insert table 1 
Insert table 2 
Insert table 3 
The hs-cTnT results are reported in table 4. 
Insert table 4 
The prevalence of the primary outcome was 4.9% (95% CI 2.2 – 7.6).  Because of the relative 
small sample size of the study and the lower than expected event rate, a multivariate regression 
analysis could not be performed to investigate associations between patient- or surgical risk 
factors and MINS.  
Discussion 
The majority of our patients were in the younger age category of 45 to 64 years with 
significantly reduced proportions in the older categories as opposed to VISION that had 50% 
of patients in the >=65-year category.  Although hypertension and malignancy were also the 
most prevalent co-morbidities, a larger proportion of patients suffered from ischaemic heart 
disease in the VISION cohort (Χ2 with Yate’s correction comparison p=0.026).  
Gynaecological surgery was significantly more common in our study (Χ2 with Yate’s 
correction comparison p<0.001).  
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The main finding of this study was that the prevalence of MINS in the elective, elevated risk 
surgical population in South Africa was comparable to reports from large, international studies.  
Three different event rates are reported (Table 4).  A 4th generation cTnT of equal to or greater 
than 0.03 ng/mL defines MINS.[5]  Debate around specific correlating values between the 4th- 
and newer 5th generation cTnT test, have led to this study regarding elevations of greater than 
33 ng/L of hs-cTnT being diagnostic of MINS.  The primary outcome of the prevalence of 
MINS was therefore 4.9% (95% CI 2.2 – 7.6).  VISION found a prevalence of MINS of 8.0% 
(95% CI, 7.5–8.4), which is not statistically different from our findings (Χ2 with Yate’s 
correction comparison p=0.078).  VISION included more than 15000 patients.  This is an 
important finding, as when compared to VISION, as we only included elective surgical patients 
with a lower cardiovascular risk profile, yet the prevalence of MINS in our cohort is similar to 
that in VISION.  This has important public health implications for South Africa, because of the 
major morbidity and mortality associated with MINS.   
Furthermore, our findings suggest that the current international cardiovascular risk prediction 
models may be inappropriate for South African patients, and/ or they may be incorrectly 
calibrated, resulting in an underestimation of cardiovascular risk in South African surgical 
patients.  Indeed, recent literature suggests that utilising the revised cardiac risk index (RCRI) 
in South African patients may be inappropriate, especially in vascular surgery.[31]  Another 
confounder might be the human immunodeficiency virus (HIV) epidemic in Southern Africa, 
where HIV-positive patients had less traditional cardiovascular risk factors, but a similar 
perioperative morbidity and mortality when compared to HIV-negative patients undergoing 
vascular surgery.[29]  The development of an appropriate (and well calibrated) perioperative 
cardiovascular risk prediction model is necessary in South Africa. 
Study Strengths and Weaknesses 
A strength of this study is the prospective screening of a specific population group (non-cardiac 
surgery patients) for whom previously there was no published data of the prevalence of MINS.  
Since the South African population still lacks population-specific prognostic values for cTnT, 
this study could form an initial contribution to future, larger studies, and provides important 
data necessary to power these studies.   
Despite screening over 1100 patients, the sample size of this study remains relatively small, 
with wide confidence intervals. This is a potential weakness, however, this was to ensure that 
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through the exclusion criteria, this study attempted to reduce the number of confounders of 
postoperative cTnT elevation (which may not have been secondary to myocardial ischaemia).  
We believe the estimate of the prevalence of MINS in this study is therefore robust.  Since the 
prevalence of MINS was only 5%, the current study appears to be underpowered.  However, it 
is possible that the prevalence may even be higher than reported here as we excluded some 
patients at high risk of cardiovascular complications, because they had comorbidities which 
may be associated with non-ischaemic cTnT release and we would not be able to confidently 
ascribe troponin elevation to MINS in these patients. A further limitation was the lack of a 
preoperative cTnT screen.  It is possible that some of the patients may have been troponin 
positive preoperatively.  The fact that the majority of patients were only subject to a single 
cTnT investigation also introduced another limitation.  Most of the international studies 
provides more than 2 days of postoperative troponin surveillance.[4,28]  Since troponin elevation 
occurs within the first 3 days following surgery, this limitation could also have reduced our 
event rate further, and result in our reduced perceived prevalence.[6] 
Conclusion 
Since the prevalence of MINS in South Africa appear to be similar to that found in international 
studies, its strong association with perioperative mortality and major morbidity suggests 
significant implications for public health outcomes in South Africa.  Furthermore, elective 
surgery has been associated with a higher mortality in South Africa compared to international 
cohorts, despite similar risk profiles.  Therefore, there is a need to address the calibration of 
cardiovascular risk models in South Africa, and/or the development of South African 
cardiovascular risk prediction models, so patients at risk can be identified early for both 
primary and secondary prevention.  International guidelines promote the utility of troponin 
surveillance, and a recent study found troponin surveillance to be financially viable in South 
Africa.[36] Our data suggest that postoperative troponin surveillance is necessary in elevated-
risk non-cardiac surgical patients. 
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Figures 
Figure 1: Flow diagram of patient recruitment
High sensitivity cardiac troponin T results
Lost = 9 Included = 244
Additional check for renal impairment
Renal exclusions = 35 253
Sampling
Sampling errors = 12 288
Consent
Declined = 1 300
Eligible patients
301
Theatre list interrogation - convenience sampling - 1100 screened
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Tables 
Table 1. Patient demographics 
Included patients (n) 244 
Male (%)  43 
Female (%) 57 
Age (mean, years) (SD) 60.5 (9.4) 
Age 45-64 (%; 95% CI) 68.9 (63.0-74.7) 
Age 65-75 (%; 95% CI) 23.8 (18.4-29.1) 
Age >75 (%; 95% CI) 6.6 (3.5-9.7) 
SD standard deviation; CI confidence interval 
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Table 2. Surgical categories 
General; n (%) 63 (25.8) 
Gynaecological; n (%) 52 (21.3) 
Orthopaedic; n (%) 40 (16.4) 
Urological; n (%) 27 (11.1) 
Vascular; n (%) 18 (7.4) 
Otolaryngological; n (%) 16 (6.6) 
Thoracic; n (%) 9 (3.7) 
Neurological; n (%) 3 (1.2) 
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Table 3. Patient comorbidities 
Median number of comorbidities (IQR) 1 (1-2) 
Hypertension; n (%) 161 (66.0) 
Malignancy; n (%) 78 (32.0) 
Smoking; n (%) 69 (28.3) 
Diabetes Mellitus; n (%) 50 (20.5) 
Hypercholesterolemia; n (%) 47 (19.3) 
Previous myocardial infarction; n (%) 20 (8.2) 
Previous stroke; n (%) 15 (6.1) 
Previous heart failure; n (%)  6 (2.5) 
IQR interquartile range 
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Table 4. High Sensitivity Cardiac Troponin T results at Groote Schuur Hospital 
cTnT undetectable; n (%) 42 (17.2) 
cTnT median (IQR) 7 ng/L (4 – 14)  
cTnT median >30 ng/L (IQR) 60 ng/L (37 – 83) 
cTnT > 99th percentile* (number, proportion) 55, 22.5%; 95% CI 17.3 – 27.8 
cTnT > 33 ng/L† (number, proportion) 12, 4.9%; 95% CI 2.2 – 7.6 
cTnT > 53 ng/L (number, proportion) 7, 2.9%; 95% CI 0.8 – 5.0 
* above 13 ng/L; † primary outcome definition; IQR interquartile range
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